ArticleFrontiers in pharmacology2026
The efficacy and safety of telitacicept and its combination with glucocorticoids in IgA nephropathy: a retrospective cohort study.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin A nephropathy (IgAN) has a high incidence rate and a poor prognosis. Currently, no ideal treatment is available for this disease. Despite some reports on the use of telitacicept in IgAN, studies with a treatment duration of 24 weeks or longer remain limited, and data on its combination with glucocorticoids are currently lacking. Methods: This retrospective cohort study enrolled 136 individuals diagnosed with IgAN via renal biopsy who exhibited 24-h urinary protein excretion (UPE) ≥ 1 g and an estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m Results: At 24 weeks, compared with baseline, median UPE decreased by 0.70 g (41.75%) in the RAS inhibitor group, by 0.92 g (62.85%) in the glucocorticoid ± immunosuppressant group, by 1.14 g (73.68%) in the telitacicept group, and by 1.34 g (81.18%) in the telitacicept + glucocorticoid group. The reduction in UPE was significantly greater in the latter three groups than in the RAS inhibitor group (p < 0.05). Moreover, the telitacicept + glucocorticoid group demonstrated a significantly greater reduction in UPE than the other groups. The eGFR decreased by 3.22 ml/min/1.73 m Conclusion: These findings indicate that in IgAN patients with a high risk of progression, telitacicept effectively reduces proteinuria and confers kidney protective effects. Furthermore, in individuals with UPE ≥2.5 g or impaired renal function, the combination of telitacicept and glucocorticoids is associated with improved rates of UPE remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.